The Oxford-AstraZeneca COVID-19 vaccine only 76% effective?
The Oxford-AstraZeneca COVID-19 vaccine only 76% effective?
The Oxford-AstraZeneca COVID-19 vaccine only 76% effective? The Oxford-AstraZeneca COVID-19 vaccine’s effective rate has been reduced to 76%, and it has been “discontinued” recently.
On March 25, AstraZeneca, a British-Swedish pharmaceutical company, said that the COVID-19vaccine developed by the company in cooperation with the University of Oxford has an effective rate of 76% in preventing disease. Prior to this, the company claimed that its vaccine has an effective rate of 79%, and was subsequently accused of the result being based on “outdated information”, which has repeatedly damaged the image of AstraZeneca’s vaccine, which has recently suffered from the “out of service” storm.
According to a Reuters report on the 25th, AstraZeneca announced on the same day that based on the analysis of the latest results, its COVID-19 vaccine is 76% effective in preventing symptomatic new coronavirus pneumonia.
According to an email sent by AstraZeneca to The Paper (www.thepaper.cn) on March 22, clinical trials involving more than 32,000 people have proved that the effectiveness of AstraZeneca vaccine in preventing symptomatic new coronavirus pneumonia is 79%. The effective rate for severe illness is 100%. These participants came from 88 trial centers in three countries: the United States, Peru, and Chile. The trial randomly allocated the vaccine group and the placebo group at a ratio of 2:1.
AstraZeneca also emphasized that this trial is the largest trial of the vaccine so far. The discovery proves that its COVID-19 vaccine is safe, and there is no increase in the risk of serious blood clots. The reason why the company emphasized the safety of vaccines so much at this time is that very few people in Europe had serious thrombosis problems after being vaccinated with AstraZeneca. People questioned the effectiveness of this vaccine. Yu Guo even suspended vaccination, waiting for the European Medicines Agency and WHO to “stamp” it for safety before resuming use.
However, this news was quickly refuted. On March 23, the National Institute of Allergy and Infectious Diseases issued a statement saying that it was concerned about the COVID-19 vaccine trial information released by AstraZeneca, because an independent data security monitoring committee in the United States was worried that AstraZeneca might use “outdated” in the trial. Information”, and this information may provide incomplete efficacy data. The US “Washington Post” reported that the committee sent a letter to AstraZeneca and believed that the effective rate should be reported as 69% to 75%.
AstraZeneca also quickly issued a statement in response, saying that its COVID-19 vaccine data released the day before was based on a pre-set interim analysis, and the data was as of February 17. Regarding the “information outdated” statement, the AstraZeneca team declined to respond to The Paper’s request for comment. On March 24, Oxford University sent an email to The Paper that AstraZeneca was reviewing the test data. According to a statement issued by AstraZeneca on the 23rd, it will announce the results of the preliminary analysis within 48 hours.
(source:internet, reference only)
Disclaimer of medicaltrend.org
